

UC San Diego

UC San Diego Previously Published Works

Title

Integrated Activity and Genetic Profiling of Secreted Peptidases in *Cryptococcus neoformans* Reveals an Aspartyl Peptidase Required for Low pH Survival and Virulence

Permalink

<https://escholarship.org/uc/item/0kq142xp>

Journal

PLOS Pathogens, 12(12)

ISSN

1553-7366

Authors

Clarke, Starlynn C

Dumesic, Phillip A

Homer, Christina M

et al.

Publication Date

2016

DOI

10.1371/journal.ppat.1006051

Peer reviewed

Integrated Activity and Genetic Profiling of Secreted Peptidases in *Cryptococcus neoformans* Reveals an Aspartyl Peptidase Required for Low pH Survival and Virulence.

Secreted Peptidases Impact Virulence of *C. neoformans*

Starlynn C. Clarke¹, Phillip A. Dumesic², Christina M. Homer², Anthony J. O'Donoghue^{1, #a},
Florenca La Greca¹, Lenka Pallova³, Pavel Majer³, Hiten D. Madhani^{2*} and Charles S. Craik^{1*}.

1 ¹ Department of Pharmaceutical Chemistry
2 University of California, San Francisco
3 San Francisco, California, United States of America

4

5 ² Department of Biochemistry and Biophysics
6 University of California, San Francisco
7 San Francisco, California, United States of America

8

9 ³ Institute of Organic Chemistry and Biochemistry
10 Academy of Sciences of the Czech Republic,
11 Prague, Czech Republic

12

13 ^{#a} Current address
14 Skaggs School of Pharmacy and Pharmaceutical Sciences
15 University of California, San Diego
16 La Jolla, California, United States of America

17

18 *Corresponding author
19 E-mail: Charles.Craik@UCSF.edu (CSC)
20 E-mail: HitenMadhani@gmail.com (HDM)

21 **Abstract**

22 The opportunistic fungal pathogen *Cryptococcus neoformans* is a major cause of mortality in
23 immunocompromised individuals, resulting in more than 600,000 deaths per year. Many human
24 fungal pathogens secrete peptidases that influence virulence, but in most cases the substrate
25 specificity and regulation of these enzymes remains poorly understood. The paucity of such
26 information is a roadblock to our understanding of the biological functions of peptidases and
27 whether or not these enzymes are viable therapeutic targets. We report here an unbiased
28 analysis of secreted peptidase activity and specificity in *C. neoformans* using a mass
29 spectrometry-based substrate profiling strategy and subsequent functional investigations. Our
30 initial studies revealed that global peptidase activity and specificity are dramatically altered by
31 environmental conditions. To uncover the substrate preferences of individual enzymes and
32 interrogate their biological functions, we constructed and profiled a ten-member gene deletion
33 collection of candidate secreted peptidases. Through this deletion approach, we characterized
34 the substrate specificity of three peptidases within the context of the *C. neoformans* secretome,
35 including an enzyme known to be important for fungal entry into the brain. We selected a
36 previously uncharacterized peptidase, which we term **Major aspartyl** peptidase 1 (May1), for
37 detailed study due to its substantial contribution to extracellular proteolytic activity. Based on
38 the preference of May1 for proteolysis between hydrophobic amino acids, we screened a
39 focused library of aspartyl peptidase inhibitors and identified four high-affinity antagonists.
40 Finally, we tested *may1Δ* strains in a mouse model of *C. neoformans* infection and found that
41 strains lacking this enzyme are significantly attenuated for virulence. Our study reveals the
42 secreted peptidase activity and specificity of an important human fungal pathogen, identifies
43 responsible enzymes through genetic tests of their function, and demonstrates how this
44 information can guide the development of high affinity small molecule inhibitors.

45

46 **Author Summary**

47 Many pathogenic organisms secrete peptidases. The activity of these enzymes often
48 contributes to virulence, making their study crucial for understanding host-pathogen biology and
49 developing therapeutics. In this report, we employed an unbiased, activity-based profiling assay
50 to examine the secreted peptidases of a fungal pathogen, *Cryptococcus neoformans*, that is
51 responsible for 40% of AIDS-related deaths. We discovered which peptidases are secreted,
52 identified their substrate specificity, and interrogated their biological functions. Through this
53 analysis, we identified a principal enzyme responsible for the extracellular peptidase activity of
54 *C. neoformans*, May1, and demonstrated its importance for growth in acidic environments.
55 Characterization of its substrate preferences allowed us to identify compounds that are potent
56 substrate-based inhibitors of May1 activity. Finally, we found that the presence of this enzyme
57 promotes virulence in a mouse model of infection. Our comprehensive study reveals the
58 expression, regulation and function of *C. neoformans* secreted peptidases, including evidence
59 for the role of a novel aspartyl peptidase in virulence.

60

61 **Introduction**

62 *Cryptococcus neoformans* is an opportunistic fungal pathogen responsible for 40% of all AIDS-
63 related deaths [1,2]. Of the one million new infections occurring worldwide annually, greater
64 than 60% result in death due to the limited efficacy and availability of therapeutics [3]. Only
65 three classes of drugs are currently approved for treatment of fungal infections, thus there is a
66 significant need for development of new antifungal compounds [3-5].

67 Peptidases are secreted by many types of pathogens including bacteria, fungi and parasites
68 and often serve critical roles related to survival and virulence [6-11]. Direct targeting of
69 peptidases expressed by pathogenic organisms has proven to be a successful therapeutic
70 strategy, notably in the development of Hepatitis C Virus (HCV) and Human Immunodeficiency

71 Virus (HIV) protease inhibitors [12,13]. Additionally, the identification and characterization of
72 peptidases secreted by pathogens have contributed to the formulation of new diagnostic
73 approaches based on detection of these proteolytic activities [14-16].

74 Pathogenic fungi express extracellular peptidases for wide-ranging functions including host
75 tissue invasion, nutrient acquisition and regulation of mating [17-19]. A single organism may
76 simultaneously secrete multiple peptidases with divergent substrate specificities and
77 requirements for activity that are tailored to their biological functions. In addition, peptidase
78 secretion and activation are often stimulated by extracellular conditions, as distinct proteolytic
79 functions can be important for different environments. *Candida albicans* and *Aspergillus*
80 *fumigatus*, two prominent fungal pathogens, each secrete several peptidases with defined roles
81 in virulence, while dermatophytes and the causative agent of white-nose syndrome
82 *Pseudogymnoascus destructans* use extracellular peptidases to degrade host tissues [20-26].
83 Multiple peptidases have been identified in the secreted proteome of *C. neoformans*, including a
84 metallopeptidase that is required for dissemination to the central nervous system (CNS) in a
85 mouse infection model [27-34]. Interestingly, the level of peptidase secretion has been shown
86 to vary between isolates in *Cryptococcus* species and in many cases higher secretion has been
87 correlated with increased virulence [35-38]. Although these findings suggest that extracellular
88 peptidases are involved in *C. neoformans* pathogenicity, the delineation of their functions and
89 their validation as therapeutic targets is limited by poor understanding of their activity, specificity
90 and regulation.

91 In this work, we used a comprehensive activity-based approach to characterize secreted
92 peptidases in *C. neoformans* culture supernatants. This strategy, termed Multiplex Substrate
93 Profiling by Mass Spectrometry (MSP-MS), relies on mass spectrometry to identify cleavage
94 events within a defined 228-member library comprising physiochemically diverse
95 tetradecapeptides [39]. The scope and design of the library allows detection of cleavage events
96 from multiple peptidases simultaneously, and the resulting data are informative for

97 understanding activity on both a global and individual enzyme level. Activity-based profiling
98 stands in contrast to traditional proteomics methods that catalog which peptidases are present
99 but do not provide information on how each enzyme contributes to the overall proteolytic activity
100 [11,27]. Likewise, candidate-based approaches focusing on single proteolytic activities isolated
101 from cultures may not accurately represent how these enzymes function within the secreted
102 peptidase milieu [31,32].

103 To investigate the secreted peptidases of *C. neoformans* and test the influence of
104 environment on global proteolytic activity, we cultured fungal cells under two different conditions
105 and then isolated the cell-free supernatants for substrate specificity profiling. These
106 experiments revealed that overall peptidase specificity differs greatly in response to extracellular
107 conditions. To uncover the contribution of individual enzymes to the total proteolytic activity, ten
108 candidate peptidases were individually deleted and conditioned media generated from each
109 mutant strain was compared to the parental strain. Through this approach, we identified and
110 defined the putative substrate preferences of three peptidases, including a previously
111 uncharacterized secreted aspartyl peptidase. We found that this enzyme is the dominant
112 contributor to extracellular endopeptidase activity at acidic pH and determined that this activity is
113 required for tolerance to low pH environments. Analysis of its substrate specificity enabled us to
114 screen an appropriately focused library of aspartyl peptidase inhibitors, which led to the
115 identification of potent *in vitro* antagonists. Finally, we found that deletion strains of this enzyme
116 are attenuated for virulence in a mouse inhalation model of *C. neoformans* infection.

117 Our in-depth characterization of extracellular peptidases in *C. neoformans* establishes a
118 framework for uncovering the biological functions of these enzymes. As demonstrated by our
119 identification of a peptidase required for virulence, examining the roles of these enzymes is
120 critical to understanding the pathogenicity of *C. neoformans*. Furthermore, the methods
121 described here are applicable to the discovery and characterization of secreted peptidases from
122 other pathogenic organisms.

123

124 **Results**

125 **Global secreted peptidase profiling in *C. neoformans* reveals abundant activity and**
126 **environment-dependent specificity** *C. neoformans* was cultured in either microbial minimal
127 media (yeast nitrogen base [YNB] pH 5.0) or mammalian tissue-culture media (DMEM pH 7.4),
128 and supernatants from each condition were assayed using a panel of internally quenched (IQ)
129 fluorogenic peptides (Fig 1A, S1 Table for sequences). These substrates were previously
130 developed to detect a broad range of microbial peptidases from diverse peptidase families [40-
131 42]. The speed and flexibility of this assay allowed us to optimize the conditions for peptidase
132 activity and to determine which class-specific inhibitors affect it.

133

134 **Fig 1. Profiling of *C. neoformans* conditioned media reveals abundant secreted**
135 **peptidase activity with environment-specific regulation.** (A) Profiling of secreted peptidase
136 activity present in YNB or DMEM media conditioned by wild-type cells using a panel of internally
137 quenched (IQ) fluorescent peptides. Columns represent mean \pm S.D. (B) Schematic of
138 Multiplex Substrate Profiling by Mass Spectrometry (MSP-MS). Conditioned media is combined
139 with a 228-member peptide library and mass spectrometry analysis is run before and after
140 incubation to identify cleavage events. Norleucine replaces methionine in the MSP-MS library
141 and is indicated by an “n” in representations of the peptides. (C) Several hundred cleavage
142 events were detected in both YNB and DMEM conditioned media profiled by MSP-MS. (D)
143 Positional profiling of all cleaved bonds detected by MSP-MS in either media type. (E) Two
144 representative examples of peptides cleaved in the MSP-MS assay by both media conditions.
145 Arrows indicate the location of cleavage sites.

146

147 Although peptidase activity was evident under both culture conditions, differential substrate
148 cleavage reflected differences in specificity. Notably, IQ-2 and IQ-6 were cleaved more
149 efficiently by peptidases in YNB media, while proportionally higher activity was observed against
150 IQ-3 and IQ-4 in DMEM media (Fig 1A). These differences suggested that alternate peptidases
151 were active in each culture condition, which was further confirmed by assaying the substrates in
152 the presence of class-specific peptidase inhibitors. This analysis revealed that aspartyl
153 peptidase activity was present in YNB conditioned media while metallopeptidase activity could
154 be detected in DMEM media (S1 Fig). Adjustment of YNB supernatants from pH 5.0 to 7.4 (the
155 pH of DMEM media) yielded only very low levels of any peptidase activity, while lowering the pH
156 of DMEM supernatants from 7.4 to pH 5.0 produced a peptidase activity pattern similar to YNB
157 media (S1 Fig). This result suggests that growth in DMEM media using mammalian cell culture
158 conditions induces peptidases optimized for neutral pH in addition to the acidic pH activities
159 detected after growth in YNB media.

160 To investigate global peptidase substrate specificity, MSP-MS was conducted on YNB and
161 DMEM supernatants at the optimal pH for activity observed for each condition, pH 5.0 and 7.4,
162 respectively. In the MSP-MS assay, peptide sequencing by LC-MS/MS is used to identify all
163 peptide cleavage products within the 228-member library, revealing peptidase substrate
164 specificity preferences (Fig 1B). The reproducibility of these substrate specificity preferences,
165 and of the cleavage events from which they derive, was confirmed by assessing three technical
166 replicate samples (S2 Fig and S2 Table). Importantly, since there are no modifications to either
167 the N- or C-termini in the peptide library, both exo- and endo-peptidases can be identified in an
168 unbiased manner.

169 Using MSP-MS we observed that peptidases in YNB media cleaved at 423 total sites,
170 whereas peptidases in DMEM media cleaved at 283 total sites (Fig 1C). Only 107 of these sites
171 were cleaved by enzymes in both samples. This difference in cleavage site preference indicated
172 that peptidase activity and specificity differs between the two culture conditions. Positional

173 analysis of all bonds cleaved within the tetradecapeptides of the MSP-MS library illustrates the
174 proportion of endo- and exo-peptidase activity in each sample (Fig 1D). In YNB supernatants,
175 the most frequently cleaved bond was the carboxyl terminal bond between amino acids thirteen
176 and fourteen, representing 32% of total proteolysis events. In fact, 137 of the 228 peptides had
177 their carboxyl-terminal amino acid cleaved. Moreover, we observed that single amino acids
178 were often sequentially hydrolyzed from the carboxyl termini of substrates until an unfavored
179 residue was reached, consistent with the presence of abundant carboxypeptidase activity. This
180 cleavage preference was not observed for proteases in the DMEM media. These studies
181 indicate that carboxypeptidase activity is more abundant in conditioned media from *C.*
182 *neoformans* cultures grown in YNB. To further illustrate the differences in proteolytic activity
183 between the two conditions, representative examples of peptides cleaved in both samples are
184 shown (Fig 1E).

185

186 **Identification of secreted peptidases by proteomic and genetic approaches** To identify
187 which *C. neoformans* peptidases may be contributing to the global substrate specificity profile,
188 we conducted a proteomic analysis of secreted proteins. We observed 199 and 131 proteins in
189 YNB and DMEM conditioned media respectively, with 52 proteins common to both conditions
190 (S3 Table). Recently, Geddes and colleagues identified 61 proteins in the secretions of *C.*
191 *neoformans* grown for 16 to 120 hours in minimal media [43], while Campell and coworkers
192 identified 22 secreted proteins after 168 hours growth in RPMI media [29]. In total, 24 of the
193 proteins detected in our study contained predicted secretion signals (SignalP 4.0) [44], 127 were
194 predicted to be non-classically secreted (SecretomeP 2.0) [45], and 17 have been associated
195 with extracellular microvesicles [46]. The remaining proteins identified had no known
196 mechanism of secretion (S3 Fig, S3 Table). Seven of the proteins with predicted signal
197 sequences were peptidases and included members of the aspartyl, metallo and serine
198 peptidase families. Both endopeptidases and carboxypeptidases were identified, consistent

199 with our predictions from analysis of *C. neoformans* extracellular proteolytic activity (Fig 1). Five
200 of these enzymes have been detected in studies of the *C. neoformans* secretome by other
201 groups; however Prc1 and CNAG_05872 have not been observed previously.

202 To determine which enzymes are responsible for the proteolytic activity present in *C.*
203 *neoformans* conditioned media, we performed targeted gene deletions on ten candidate
204 secreted peptidases (Table 1, S4 Table). Of the seven aforementioned peptidases with
205 predicted signal sequences that were identified by our secretome proteomics, one was
206 predicted to be GPI-anchored (CNAG_04380) [27,47], and thus excluded from further analysis,
207 as our study was focused on non-cell wall anchored enzymes. One other peptidase could not
208 be mapped unambiguously to a single gene, as three paralogs of this enzyme exist in the *C.*
209 *neoformans* var *grubii* genome [48]. Therefore, all three genes were individually targeted for
210 deletion (CNAG_00919, CNAG_01040 and CNAG_02966). Because these genes are unnamed
211 and lack orthologs in *Saccharomyces cerevisiae*, we propose naming them **Carboxypeptidase D**
212 **1, 2** and **3** (CXD1-3), respectively. This resulted in eight genes deleted based on our
213 proteomics results (Table 1, S4 Table). We additionally targeted two secreted peptidases that
214 were not identified here but have been reported in previous proteomics studies [27]. Two
215 independent isolates of each of the ten deletion strains were generated and are indicated in the
216 text and figures by the gene name or CNAG number followed by “-1” or “-2” (S4 Table).

217

218 **Table 1. Peptidase deletion strains generated in this study.** Gene names were determined
219 where possible by following the recommended naming guidelines for *C. neoformans* [49]. *Nat^R*
220 is nourseothricin resistance. An asterisk indicates the observation of a phenotype in
221 subsequent mutant characterization studies (S8-9 Fig). Evidence for activity in YNB or DMEM
222 conditioned media was determined in subsequent experiments analyzing proteolytic activity in
223 media conditioned by the peptidase deletion strains (Fig 2-3, S4-5 Fig). Proteins identified in

224 the present study's secretome proteomics are indicated.

225

Genotype	Name	Peptidase Type	Proteomics identification	Evidence for activity		Prior secretome identification
				YNB	DMEM	
<i>CNAG_05973Δ::Nat^R</i>	<i>SCX1</i>	Serine carboxypeptidase				[27]
<i>CNAG_06640Δ::Nat^R</i>	<i>PRC1</i>	Serine carboxypeptidase	+			
<i>CNAG_00919Δ::Nat^R</i>	<i>CXD1</i>	Carboxypeptidase D	+	+		[27]
<i>CNAG_01040Δ::Nat^R</i>	<i>CXD2</i>	Carboxypeptidase D	Predicted homolog			[48]
<i>CNAG_02966Δ::Nat^R</i>	<i>CXD3</i>	Carboxypeptidase D	Predicted homolog			[48]
<i>CNAG_00150Δ::Nat^R</i>	-	Serine endopeptidase				[27]
<i>CNAG_04625Δ::Nat^R</i>	<i>PRB1*</i>	Serine endopeptidase	+			[27]
<i>CNAG_00581Δ::Nat^R</i>	<i>PEP4*</i>	Aspartyl endopeptidase	+			[27]
<i>CNAG_05872Δ::Nat^R</i>	<i>MAY1*</i>	Aspartyl endopeptidase	+	+		
<i>CNAG_04735Δ::Nat^R</i>	<i>MPR1</i>	Metallo endopeptidase	+		+	[27]

226

227 Based on our characterization of secreted peptidase activity present in wild type
 228 *C. neoformans*, we selected deletion strains for in-depth substrate profiling analysis by MSP-MS
 229 under either DMEM or YNB culture conditions. Subsequently, by comparing the secreted
 230 peptidase activity in conditioned media from the wild type and mutant strains, we were able to
 231 correlate extracellular proteolytic activities to specific candidate enzymes.

232

233 **DMEM conditioned media contains a metallopeptidase Mpr1 and trypsin-like**
 234 **endopeptidase activity** To analyze the peptidase substrate specificity of DMEM media
 235 conditioned by wild-type cells, we generated a frequency plot from the 283 cleavage events
 236 detected by MSP-MS (Fig 2A, S5 Table) [50]. The amino acid preferences are shown for four
 237 positions on either side of the cleaved bond (P4-P4'), as the majority of substrate specificity is
 238 determined by residues closest to the scissile bond. This analysis revealed that peptidases in

239 DMEM supernatants prefer positively charged residues on either side of the cleaved bond, as
240 well as hydrophobic residues in the P1' position. Negatively charged amino acids are
241 disfavored at the majority of positions, and proline and glycine are both highly disfavored in
242 most positions from P2-P2' (Fig 2A).

243 **Fig 2. DMEM conditioned media contains a metallopeptidase and trypsin-like**
244 **endopeptidase activity.** (A) The peptidase substrate specificity profile of DMEM media
245 conditioned by wild type. Residues are significantly favored or disfavored as determined by the
246 frequency of detection in substrates versus the frequency of the residue in the peptide library, p
247 < 0.05 . (B) Substrate specificity profile of peptidase activity from *mpr1Δ* conditioned media, $p <$
248 0.05 . (C) Peptidase substrate specificity profile constructed from cleavage events detected in
249 wild type but not *mpr1Δ*, $p < 0.05$. (D) A representative peptide cleaved by peptidases in both
250 wild type and *mpr1Δ* conditioned media.

251

252 To identify the enzymes responsible for this activity, we examined proteolytic activity in
253 peptidase deletion strains. Because DMEM conditioned media contained metallopeptidase
254 activity (S1 Fig) and a single metallopeptidase (Mpr1) was identified by proteomics (Table 1, S3
255 Table), we began by investigating the contribution of this enzyme to the global specificity profile.
256 Mpr1 had previously been characterized as a secreted factor that is important for *C. neoformans*
257 invasion of the CNS [28]. Matched comparison of the substrate specificity profiles obtained
258 from DMEM media conditioned by wild type or *mpr1Δ* cells revealed that Mpr1 deficiency
259 caused a loss of the P1' preference for hydrophobic amino acids seen in wild type (Fig 2A-B).
260 However, the selection for positively charged residues on either side of the cleaved bond
261 remained unaltered and the same amino acids were disfavored in most positions.

262 To further analyze the impact of *MPR1* deletion, a Venn diagram was used to compare the
263 overlap of cleavage events between wild type and *mpr1Δ* (Fig 2C). A majority of cleaved

264 peptides were detected in both samples; however 107 cleavage events were detected in wild
265 type but not media conditioned by *mpr1Δ*. These cleavages, presumed to be absent due to the
266 loss of this enzyme, were used to generate a frequency plot representing the putative specificity
267 of Mpr1 (Fig 2C). A prominent feature of this substrate specificity profile is enrichment for
268 phenylalanine, leucine and norleucine (a replacement for methionine in the MSP-MS library) at
269 the P1' position, a result that is consistent with the specificity of other peptidases predicted to be
270 related to this enzyme (members of the M36 peptidase family) [51]. It is also notable that the
271 P1' site exhibits the greatest degree of selectivity of any position from P4-P4'. To further
272 illustrate the changes in substrate specificity observed in the *mpr1Δ* deletion strain, a
273 representative example of a peptide cleaved by enzymes in both wild type and *mpr1Δ*
274 supernatants is shown (Fig 2D).

275 An additional activity in DMEM media conditioned by wild type displays a trypsin-like
276 preference for proteolysis between two positively charged residues, indicating the presence of
277 serine peptidase activity [51]. This specificity is particularly evident in the *mpr1Δ* culture media
278 (Fig 2B). Two serine endopeptidases were present in the deletion collection and DMEM
279 conditioned media was analyzed from both strains (*prb1Δ* and *CNAG_00150Δ*). Deletion of
280 either gene did not substantially impact the extracellular peptidase activity profile, suggesting
281 functional redundancy or the existence of additional, unidentified peptidases (S4 Fig). One
282 predicted serine peptidase with a secretion signal, *KEX2*, was identified in a genome search.
283 However, our attempts to delete this gene were unsuccessful, indicating it may be essential for
284 *C. neoformans* survival.

285 In some cases, media conditioned by knockout cells produced additional peptide
286 cleavage sites as compared to wild type conditioned media, despite similar overall peptidase
287 specificity profiles (e.g., S4 Fig C). This observation is consistent with the fact that iterative
288 cleavage of an MSP-MS substrate peptide can hinder identification of a given cleavage event

289 due to loss of the cleavage's reaction product. In this way, the loss of a minor peptidase activity
290 can result in the appearance of new cleavage sites [25].

291

292

293 **An aspartyl endopeptidase May1 and the carboxypeptidase Cxd1 are the major activities**

294 **in conditioned YNB media.** A substrate specificity profile constructed from the 423 cleavages

295 observed in YNB media conditioned by wild-type cells indicated a preference for hydrolysis

296 between hydrophobic residues, while positively charged residues, proline and glycine are

297 disfavored (Fig 3A). From positional analysis of these cleavage sites, we identified

298 carboxypeptidase activity as the dominant proteolytic activity in this media (Fig 1D). Since

299 carboxypeptidases cleave the carboxyl-terminal bond, no enrichment of amino acids is evident

300 in the P2' to P4' positions in these substrates (Fig 3A).

301 **Fig 3. May1 and Cxd1 are the major proteolytic activities in YNB conditioned media.** (A)

302 The substrate specificity profile of YNB media conditioned by wild type, $p < 0.05$. (B) The

303 substrate specificity profile of the carboxypeptidase D deletion strain *cx_d1 Δ* , $p < 0.05$. (C) The

304 substrate specificity profile of the aspartyl peptidase deletion strain *may1 Δ* , $p < 0.05$. (D)

305 Positional profiling of all bonds cleaved within the tetradecapeptides of the MSP-MS library. (E)

306 A representative example of a peptide in the MSP-MS library cleaved by wild type and both

307 deletion strains. (F) Deletion of May1 abolishes endopeptidase activity against IQ-2. Columns

308 represent mean \pm S.D.

309

310 To determine whether any of the three carboxypeptidase D paralogs we identified in our

311 proteomics analysis were responsible for the observed carboxypeptidase activity, the gene for

312 each enzyme was deleted and conditioned media from the resulting mutant strains (*cx_d1 Δ* ,

313 *cx_d2 Δ* and *cx_d3 Δ*) was profiled by MSP-MS. After comparison of the specificity profiles, it was

314 clear that the carboxypeptidase specificity was most dependent on Cxd1. In media conditioned
315 by this deletion strain only 17 primary carboxyl-termini were cleaved, as compared to 137 in wild
316 type (Fig 3B, D-E). By comparison, 134 and 123 primary carboxyl-termini were cleaved in
317 media conditioned by *cxd2Δ* and *cxd3Δ*, respectively, suggesting that these enzymes do not
318 contribute substantially to the extracellular carboxypeptidase activity (S5 Fig, S5 Table). As
319 anticipated, endopeptidase cleavages were not affected in any of the three carboxypeptidase
320 deletion strains (Fig 3B, 3D, S5 Fig).

321 Fluorogenic assays demonstrated aspartyl endopeptidase activity in wild type YNB
322 supernatants (S1 Fig). To assign activity to the candidate aspartyl peptidases, conditioned YNB
323 media was profiled from the two aspartyl peptidase deletion strains listed in Table 1
324 (*CNAG_05872Δ* and *pep4Δ*). Proteolytic activity remained unchanged relative to wild type in
325 the *pep4Δ* strain (S5 Fig). In contrast, *CNAG_05872Δ* conditioned media exhibited a near-total
326 loss of endopeptidase cleavage events as well as substantially decreased carboxypeptidase
327 activity as evidenced by proteolysis of only 55 primary carboxyl termini (Fig 3C-E). This result
328 suggests that *CNAG_05872* is the dominant endopeptidase under these culture conditions.
329 This finding is consistent with fluorogenic assays, where deletion of *CNAG_05872* led to a loss
330 of endopeptidase activity in conditioned YNB media, while all other strains exhibited activity
331 levels similar to wild type (Fig 3F, S6 Fig). As the putative dominant endopeptidase, we
332 propose renaming *CNAG_05872* to **Major Aspartyl peptidase 1 (MAY1)**.

333
334 **May1 is a pepsin-like aspartyl peptidase, with optimal expression and activity at acidic**
335 **pH.** Due to its substantial contribution to peptidase activity in YNB supernatants, we performed
336 an in-depth biochemical characterization of May1. This enzyme consists of a 16 residue
337 secretory signal (SignalP 4.0) [44] followed by an 82 residue prodomain (Fig 4A). The
338 prodomain is positively charged (pI = 9.97), which likely facilitates interaction with the negatively

339 charged catalytic domain ($pI = 4.03$) at neutral or slightly acidic pH [52]. The pepsin-like
340 aspartyl peptidase domain includes residues 100-434 and is expected to auto-activate in acidic
341 environments, causing release of the pro-domain. The N-terminal region (position 101-223) is
342 also an N-terminal xylanase inhibitor domain, TAXi_N [53]. Homology between xylanase
343 inhibitors and fungal aspartyl peptidases has been noted previously and likely indicates an
344 evolutionary relationship [54].

345

346 **Fig 4. May1 is a member of the pepsin-like aspartyl peptidase family with optimal**

347 **expression and activity at acidic pH.** (A) The domain architecture of May1. The catalytic
348 aspartic acids are indicated by stars. (B) pH titration of May1 activity using IQ-2. Averages and
349 standard deviation (S.D.) of triplicates are shown. (C) Immunoblot detection of May1 tagged
350 with a CBP-2xFLAG tag in supernatants after culturing in YNB for different lengths of time. (D)
351 Activity against IQ-2 in conditioned media from wild type *C. neoformans* grown in unbuffered or
352 pH 6.5 buffered YNB. All samples were adjusted to pH 4.5 prior to being assayed. Columns
353 represent mean \pm S.D.

354

355 May1 readily cleaves IQ-2 between phenylalanine and leucine (S1 Table, S6 Fig), which
356 allowed us to use fluorogenic assays to monitor enrichment of this enzyme from YNB
357 supernatants and investigate the impact of pH on its activity. Ion exchange chromatography
358 was used to enrich May1 from conditioned YNB media, resulting in a 292 nM peptidase stock
359 solution. May1 was diluted from this stock into buffers ranging from pH 1.5 to 7.0 and activity
360 against IQ-2 was tested. Optimal activity was observed between pH 3.5-4.5, a range that is
361 consistent with other members of the aspartyl peptidase family of enzymes (Fig 4B) [55]. The
362 aspartyl peptidase antagonist pepstatin A fully inhibited proteolysis of IQ-2 in this assay,
363 providing further verification that May1 is the predominant endopeptidase activity under these

364 conditions.

365 To investigate the time- and growth-dependent secretion of May1, we added a CBP-
366 2xFLAG tag to the carboxyl-terminus through homologous recombination. By monitoring activity
367 using IQ-2, we confirmed that the addition of this tag did not diminish May1 activity in YNB
368 conditioned media. Interestingly, although recombinant May1 activity could be detected in the
369 culture supernatant after overnight growth, it could not be detected by immunoblot even after
370 three days of growth. We hypothesized that the enzyme rapidly hydrolyses the C-terminal tag;
371 therefore pepstatin A was added to the culture to inhibit this processing. This inhibitor also
372 prevented activation of pro-May1 to mature May1, resulting in the observation of only the pro
373 form of recombinant May1. Under these conditions the protein was detected by immunoblot
374 after 48 hours of growth (Fig 4C). The apparent molecular weight of pro-May1 was
375 approximately 13 kDa greater than the predicted 56.8 kDa for the tagged enzyme, suggesting
376 that this protein could contain post-translational modifications. When *C. neoformans* was
377 cultured in YNB media buffered to pH 6.5, the May1 activity detectable in supernatants using
378 IQ-2 was approximately 10-fold lower than in unbuffered YNB, and no signal could be seen by
379 immunoblot after 48 hours of growth (Fig 4D). This result suggests that low extracellular pH
380 could stimulate May1 secretion and activation.

381

382 **May1 activity is required for wild-type saturation density in YNB cultures.** We observed
383 that *may1Δ* strains grown in YNB had a lower cell density at saturation than wild type or any of
384 the other nine peptidase deletion strains (Fig 5A, S7 Fig, S6 Table). Higher cell density could
385 not be achieved by the *may1Δ* strains even after culturing for 96 hours. These data suggested
386 that *may1Δ* strains were not merely slow to replicate but were incapable of growth at high
387 density. In fact, during the exponential growth phase, *may1Δ* strains had an average doubling
388 time of 2.36 hours, which was on par with the other nine peptidase deletion strains. However,

389 all other deletion strains exhibited wild-type saturation densities (S6 Table).

390

391 **Fig 5. May1 activity is required for wild-type growth at acidic pH.** (A) Culture density was
392 recorded over time by measuring OD₆₀₀ of cultures grown in YNB. The average density and
393 S.D. of triplicates are shown. (B) Culture density of wild-type *C. neoformans* grown in YNB
394 containing 2 μM pepstatin A was recorded. Mock indicates DMSO treatment. The average and
395 S.D. of cultures grown in triplicate are shown. (C) Mutant characterization assays were
396 conducted using YNB agar plates. Cultures were adjusted to an OD₆₀₀ of 5 and then spotted in
397 10-fold serial dilutions on plates. (D) Full rescue of *may1Δ* saturation density in YNB was
398 observed after buffering to pH 6.5. Average density and S.D. of triplicates are shown.

399

400 Studies of deletion strains did not clarify whether whether May1 activity, as opposed to
401 simply the presence of the May1 protein, was required to reach a saturation density equivalent
402 to wild type. Therefore, we assessed growth of wild type *C. neoformans* in the presence and
403 absence of pepstatin A. Treatment of wild type cultures with this aspartyl peptidase inhibitor
404 resulted in a saturation density defect equivalent to that observed for the *MAY1* deletion strains
405 (Fig 5B). Importantly, no additional defects were seen in *may1Δ* strains in the presence of the
406 inhibitor, suggesting that the growth defect observed in wild-type cells treated with pepstatin A
407 was mediated through inhibition of May1.

408

409 **Mutant characterization assays reveal a *may1Δ* growth defect at low pH.** Plating assays
410 on various stress conditions were conducted with two independent isolates of each of the ten
411 peptidase deletion strains (S8-S9 Fig). After 48 hours *may1Δ* strains exhibited a growth defect
412 at pH 3.5 but not at pH 5.0 or 6.5 (Fig 5C). Longer growth periods at pH 3.5 did not allow
413 *may1Δ* colonies to overcome this sensitivity and after three days of growth, it became apparent

414 that *may1Δ* colonies also had a slight defect at pH 5.0 but not pH 6.5 (S8 Fig). None of the
415 other peptidase deletion strains displayed sensitivity to acidic pH, although *pep4Δ* was sensitive
416 to hydrogen peroxide and SDS, and *prb1Δ* had a slight sensitivity to hydrogen peroxide (S8-9
417 Fig). Based on this result, we hypothesized that the inability of *may1Δ* strains to reach wild-type
418 saturation densities in YNB was a result of acidification of the media and would be rescued by
419 buffering the media to pH 6.5. These culture conditions fully rescued the saturation density of
420 *may1Δ* (Fig 5D). Surprisingly, it also allowed the final saturation densities of both wild type and
421 *may1Δ* cultures to approximately double, revealing that low pH is a condition limiting growth
422 even for wild-type *C. neoformans*.

423 We also assessed melanization, an established virulence factor, for each of the ten
424 peptidase deletion strains. Because melanin production occurs extracellularly, we hypothesized
425 that this process could be influenced by secreted peptidase activity. Only the serine
426 endopeptidase deletion strain *prb1Δ* exhibited a hypomelanization phenotype (S9 Fig).

427
428 **A screen of an aspartyl peptidase inhibitor library yields compounds antagonistic to**
429 **May1.** While pepstatin A inhibits May1 with an IC₅₀ of 1.4 nM, it is a broad acting antagonist of
430 many members of the aspartyl class of peptidases, thereby limiting its utility. To determine
431 whether additional inhibitors targeting May1 could be obtained, we conducted an *in vitro* screen
432 using knowledge of May1 substrate specificity derived from MSP-MS analysis. We screened a
433 panel of 21 peptidomimetic molecules with similarities to May1 substrate preferences but with a
434 non-cleavable bond between the P1 and P1' position (S7 Table). Compounds 1 to 11 are linear
435 peptidomimetics, while compounds 12 through 21 are macrocycles (S7 Table) [56-59]. We also
436 screened ten HIV protease inhibitors because some of these molecules have been reported to
437 inhibit *C. neoformans* peptidase activity [60,61].

438 May1 was incubated with 100 μM, 10 μM and 1 μM of each inhibitor and activity was
439 detected using IQ-2 (Fig 6A, S10 Fig). IC₅₀ values were then calculated for the most potent

440 compounds. The best inhibition by an HIV protease inhibitor was observed with BrecaNavir,
441 which reduced activity by 80% at 1 μ M and had an IC₅₀ of approximately 352 nM (S10 Fig).
442 Among the peptidomimetic molecules, the macrocycles were the most potent, with the best
443 compounds (15 to 21) containing P2 – P3' tethered side chains, statines in P1 and an α -amino
444 acid in P2' (Fig 6, S7 Table). Compounds 16, 21, and 18 all exhibited nanomolar IC₅₀ values of
445 1.6 nM, 9.4 nM and 41 nM, respectively (S10 Fig). Among the linear peptidomimetic inhibitors,
446 those with a phenylstatine or hydroxyethylamine scissile bond isoster (compounds 4, 7, 8 and
447 11) were superior to compounds with a reduced bond (1, 2, 5, 6 and 9) or a homo-amide (2).
448 Compound 4 was the most potent May1 antagonist out of this group of inhibitors, with an IC₅₀ of
449 3.1 nM (S10 Fig).

450 From analysis of the four most effective inhibitors identified in our screen (compounds 4,
451 16, 18 and 21), it is clear that a phenylalanine side chain, either unsubstituted (4 and 16) or with
452 a small substituent (18 and 21), is preferred in P1 while a bulkier P1 side chain leads to
453 decreased potency, for example compounds 17, 19 and 20. These results match the P1
454 substrate preference for phenylalanine that we had predicted for May1 and fit our expectations
455 that bulkier residues such as tryptophan are not well tolerated in this position (Fig 3, Fig 6B).
456

457 **Fig 6. A screen of aspartyl peptidase inhibitors uncovers compounds antagonistic to**
458 **May1.** (A) Three groups of compounds were screened for inhibition of May1 activity using IQ-2.
459 Compounds completely inhibiting May1 at 1 μ M are denoted with red triangles. Averages and
460 S.D. of triplicates are shown. (B) The structures of three macrocyclic compounds screened for
461 inhibition of May1. (C) The IC₅₀ for the most potent May1 inhibitor (compound 16) was found to
462 be 1.6 nM, while peptstatin A had an IC₅₀ of 1.4 nM. The average and S.D. of measurements in
463 triplicate are shown. (D) Density at saturation (after 48 hours of growth) is shown for YNB
464 cultures of wild type *C. neoformans* treated with May1 inhibitors. Average values and S.D. of

465 triplicates are shown.

466

467 Next, we selected the two best *in vitro* hits to test their potency in culture relative to
468 pepstatin A by measuring inhibition of May1 and restriction of culture growth using fluorogenic
469 assays and OD₆₀₀ respectively. Wild-type *C. neoformans* was grown in YNB treated with 5 μM,
470 1 μM or 0.1 μM of compound 4, 16 or pepstatin A and the culture density and May1 activity
471 were measured at saturation. While compound 16 exhibited an *in vitro* IC₅₀ comparable to
472 pepstatin A, it was not as effective at inhibiting May1 activity or restricting culture growth (Fig
473 6D, S11 Fig). Curiously, despite having an *in vitro* IC₅₀ approximately twice that of compound
474 16, compound 4 was better at inhibiting culture growth. None of the three compounds affected
475 the culture density of a *may1Δ* strain, consistent with the idea that May1 is the compounds'
476 relevant target in this context (S11 Fig). These results demonstrate that May1 can be targeted
477 by small molecule inhibitors and provide a discovery framework for further inhibitor
478 development. However, additional medicinal chemistry efforts are necessary for *in vivo*
479 applications. Therefore, subsequent studies investigating the role of May1 in virulence were
480 carried out using deletion strains of this enzyme.

481

482 **May1 is required for virulence.** Because *may1Δ* strains exhibit phenotypes in both peptidase
483 activity assays and growth at low pH, we examined the role of this protein in virulence using an
484 established mouse inhalation model of Cryptococcal infection [81]. Wild-type cells were mixed
485 with an equivalent number of *may1Δ* cells and used to infect mice intranasally (Fig 7A). These
486 experiments were conducted with two independent isolates of *may1Δ* as well as a negative
487 control known not to affect fungal replication in this assay (*sxi1Δ*) [63]. Ten days after infection,
488 mouse lungs were harvested and plated for colony forming units (CFUs), at which point *may1Δ*
489 strains contributed only 22 ± 3% of the colonies recovered from the lungs, a substantial

490 decrease from the approximately 50% present upon infection. This result reveals that *may1Δ*
491 cells have a growth defect within a mammalian host because the ratio between deletion strain
492 and wild type cells was reduced after host infection.

493

494 **Fig 7. May1 is required for virulence in a mouse inhalation model of infection.** (A) Three
495 mice per group were infected with a 1:1 ratio of wild type to mutant cells using the mutant
496 strains *may1Δ-1*, *may1Δ-2* or *sxi1Δ*. The 1:1 ratio of wild type to mutant strain was confirmed
497 by plating the inoculums on plates containing nourseothricin as a selection agent. Ten days
498 after infection, lungs were harvested and plated to determine the ratio of wild type to deletion
499 strain. Average values and S.D. are shown. DPI: days post infection. (B) Ten mice per group
500 were infected with wild type, *may1Δ-1* or *may1Δ-2* cells. Significance was determined by a log-
501 rank test, ** indicates $p < 10^{-5}$.

502

503 Given the defect in *may1Δ* cell accumulation in the lung, we evaluated the role of May1
504 during *Cryptococcus* interaction with macrophages. Opsonized wild type and *may1Δ* strains
505 were phagocytosed with equal efficiency by bone marrow-derived macrophages (S12 Fig A).
506 We next tested the ability of *may1Δ* cells to accumulate within macrophages after phagocytosis,
507 since the phagolysosome environment may represent a low-pH setting in which May1 is active.
508 Indeed, cells lacking May1 accumulated significantly more slowly within macrophages than did
509 wild type cells (S12 Fig B), consistent with a role for May1 within host cells.

510 The defect in accumulation of *may1Δ* cells during intranasal infection and within
511 macrophages suggested that these strains would be attenuated for virulence. We directly
512 investigated the virulence of *may1Δ* strains by performing monotypic infections [62]. Ten mice
513 per group were infected intranasally with wild type, *may1Δ-1* or *may1Δ-2* cells (Fig 7B). Loss of

514 May1 caused significant attenuation of virulence, with mice infected by *may1Δ-1* or *may1Δ-2*
515 exhibiting a mean survival time of 60.1 and 60.7 days respectively, whereas those infected by
516 wild type had a mean survival time of 25 days. The results from these *in vivo* experiments
517 indicate an important role for May1 during mammalian infection.

518

519 **Discussion**

520 In this work, we investigated secreted proteolytic activity in *C. neoformans* var. *grubii* culture
521 media using an unbiased approach that can detect both endo- and exo-peptidase activity. In
522 combination with proteomic methods and single gene deletion approaches, this strategy allowed
523 us to characterize peptidase activity from a global perspective as well as interrogate the roles of
524 individual enzymes in the *C. neoformans* secretome. By comparing the overlap in peptidase
525 activity between wild type and these deletion strains, we were able to identify and define the
526 substrate specificities of a carboxy, aspartyl and metallopeptidase which contribute substantially
527 to the total peptidase activity profile. Additionally, we delineated the substrate specificity of an
528 unidentified trypsin-like peptidase activity, an intriguing result given previous reports implicating
529 secreted serine peptidases in *C. neoformans* pathogenicity [31,34].

530 Deletion of some peptidase genes, such as the predicted carboxypeptidase D genes *CXD2*
531 and *CXD3*, caused no significant change in secreted proteolytic activity or cellular phenotype.
532 Instead, it appears that a third carboxypeptidase D paralog *CXD1* is responsible for the majority
533 of exopeptidase activity under these conditions. The broad specificity of Cxd1 suggests that
534 one possible role for this enzyme could be in nutrient acquisition by providing *C. neoformans*
535 with free amino acids from extracellular protein sources [17,18,64].

536 The serine peptidase deletion strain *prb1Δ* also had a minimal effect on total secreted
537 peptidase activity; however, a phenotype of reduced melanin production was evident, indicating
538 function under these conditions (S9 Fig). One possibility is that this gene encodes an enzyme

539 with very strict substrate specificity, thus its deletion did not have a substantial impact on total
540 extracellular peptidase activity as measured by the MSP-MS assay (S4 Fig).

541 Through the application of our global profiling approach to different culture conditions, we
542 were able to demonstrate that the landscape of secreted peptidase activity shifts in response to
543 alterations in environment. This result raises the possibility that changes in extracellular
544 proteolytic activity could be relevant for adaptation. For example, we detected the activity of the
545 metallopeptidase Mpr1 only after growth under neutral pH conditions, whereas we find that
546 May1 is optimally active under acidic conditions. Thus, these enzymes may function in different
547 settings within the host or within other environments encountered by *C. neoformans*.

548 Through proteolytic profiling and mutant characterization assays, we identified the aspartyl
549 peptidase May1 as the dominant endopeptidase at low pH and found that its activity is required
550 for tolerance to acidic environments. The strongest determinant of May1 substrate specificity
551 was shown to be a preference for cleavage between hydrophobic residues, in particular
552 phenylalanine, leucine and norleucine (Fig 3A). Based on these results, we screened a focused
553 panel of aspartyl peptidase inhibitors with similarity to the P1-P1' substrate specificity of May1.
554 Several of these compounds had IC₅₀ values in the nanomolar range, whereas the HIV protease
555 inhibitors had relatively poor affinity for May1. Previous reports have shown that some HIV
556 protease inhibitors reduce secreted aspartyl peptidase activity produced by *C. neoformans*
557 [60,61]. The concentrations of inhibitors required to achieve statistically significant inhibition in
558 previous studies were much higher than those used in the experiments reported here although
559 the trends for inhibitor potency match our results [60]. Therefore, it is possible that the inhibition
560 of *C. neoformans* aspartyl peptidase activity seen in previous publications could be explained by
561 the inhibition of May1.

562 We found that strains lacking May1 are attenuated in a competition infection assay, a
563 macrophage accumulation assay and a monotypic infection assay. In microbial culture it is
564 likely that May1 cleaves one or more secreted or cell wall-bound fungal proteins to facilitate low

565 pH tolerance. However, it is possible that during an infection May1 cleaves host proteins and
566 either or both of these proteolytic events impacts virulence. An additional important
567 consideration for defining the role of May1 in *C. neoformans* pathogenicity is the cleavage
568 context within the host. Our pH titration determined that May1 has very low levels of activity
569 above pH 6.5; however few environments of lower pH than this exist within the mammalian host.
570 Therefore, it is possible that residual May1 activity at neutral pH is important, or alternatively
571 that May1 could be relevant for survival in acidic host environments such as dendritic cell or
572 macrophage phagolysosomes, which exhibit a pH of ~5.0 in the context of Cryptococcal
573 phagocytosis [65,66]. A third possibility is that a combination of these factors contributes to the
574 attenuated virulence of *may1Δ* strains.

575 We have identified orthologs of *MAY1* in many other basidiomycetes including the
576 opportunistic pathogens *Trichosporan asahii* and *Cryptococcus gattii*, the latter of which is
577 capable of infecting immunocompetent individuals [67] [48]. Many pathogenic ascomycetes
578 also contain *MAY1* orthologs, including *Histoplasma capsulatum*, *Coccidioides immitis* and
579 *Aspergillus* species, although the sequence identity is low [48]. None of the *MAY1* orthologs in
580 basidiomycetes has been well studied and only one ortholog in an ascomycete has been
581 examined. This enzyme, from *A. fumigatus*, encodes a protein secreted during infection of the
582 virulence model *Galleria mellonella* [68]. The hypovirulent phenotype observed in *C.*
583 *neoformans may1Δ* strains and the identification of May1 orthologs in other fungal pathogens
584 raises the possibility that this peptidase family displays a conserved virulence function and
585 suggests that the roles of these orthologs are important to investigate.

586 Small molecule drug development requires a thorough understanding of the target
587 enzyme as well as the surrounding peptidase milieu [69-73]. The results described in this report
588 lay the groundwork for investigating the functions of *C. neoformans* secreted peptidases and the
589 use of inhibitors to modulate their activity. The substrates and inhibitors presented here may
590 also be of value for interrogating related fungal peptidases. Furthermore, our approach to

591 investigating secreted peptidases through integration of activity profiling, proteomics, and
592 genomics strategies is broadly applicable to other genetically tractable pathogens.

593

594 **Materials and Methods**

595 **Ethics statement:** Studies in mice were carried out according to the recommendations in the
596 Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All
597 protocols were reviewed and approved by the Institutional Animal Care and Use Committee,
598 University of California, San Francisco, approval number AN091509-02C. During infections,
599 mice were anesthetized by an intraperitoneal injection of ketamine (75 mg/kg) and
600 dexmedetomidine (0.5 mg/kg), which was reversed by an intraperitoneal injection of
601 atipamezole (1.5 mg/kg). Mice were sacrificed in accordance with protocol guidelines by CO₂
602 inhalation and cervical spine dislocation.

603

604 **Peptide-based detection of peptidase activity and characterization of substrate** 605 **specificity**

606 **Fluorogenic peptide assays:** Assays were conducted at room temperature on a Biotek
607 Synergy H4 plate reader in a 50 μ l volume using 96-well round bottom, polystyrene plates
608 (Corning) with λ_{ex} 328 nm λ_{em} 393 nm unless otherwise stated. Substrates were each 7 or 8
609 amino acids with 7-methoxycoumarin-4-acetic acid or 7-methoxycoumarin-4-yl-acetyl-L-lysine
610 on the amino terminus, and at the carboxyl terminus 4-dinitrophenyl-L-lysine or 4-dinitrophenyl
611 bound directly to the carboxyl terminus as indicated (For sequences see S1 Table). Substrates
612 were assayed at a 10 μ M final concentration from DMSO stocks. Biotek Gen5 software was
613 used to calculate initial velocities in relative fluorescent units per second (RFU/sec) from 20
614 points over the linear portion of each assay. To assay activity, YNB conditioned media was
615 adjusted to pH 4.5 using 100 mM MES, 100 mM NaCl buffer, pH 6.5 at a final concentration of

616 26 mM MES, 26 mM NaCl, unless otherwise stated. Conditioned DMEM media was first buffer
617 exchanged into PBS using a centrifugal filter unit with a 3 kDa cutoff (Millipore) before use. The
618 peptidase inhibitors pepstatin A, 1-10-phenanthroline, AEBSF and E64 were dissolved in DMSO
619 and were obtained from Sigma-Aldrich.

620 **Multiplex substrate profiling by mass spectrometry:** Full methods are available elsewhere
621 [39]. Minor modifications to the published method are as follows: The library contained 104
622 additional tetradecapeptides designed using the same algorithm as published for a total of 228
623 synthetic peptides. The library was split into two pools of 114 peptides to optimize detection by
624 LC-MS/MS and 500 nM of each peptide was present in the assay. YNB supernatants (32 hour
625 cultures) were adjusted to pH 5 and diluted 1:2 in fresh YNB prior to assaying by MSP-MS,
626 whereas DMEM supernatants (32 hour cultures) were buffer exchanged into PBS and used
627 undiluted in the assay. The assay was conducted at room temperature and samples were
628 removed at the time points defined [39].

629 Mass spectrometry was conducted on either the LTQ Orbitrap XL or an LTQ FT machine as
630 described [39]. The full length sequences of all substrates were then deduced by comparison to
631 the intact peptides found in the library using the Protein Prospector program v5.10.15 (UCSF),
632 and an excel format of the results was generated using the Extractor program (UCSF) [39,74].
633 The frequency with which each amino acid was detected in the P4 to P4' positions was
634 illustrated using iceLogo software [50]. All possible P4 to P4' sequences in the 228-member
635 library were used as the reference dataset (S5 Table).

636

637 **Proteomics**

638 Conditioned media was prepared from wild type *C. neoformans* cultured in YNB (32 hours) or
639 DMEM (48 hours) as described below and concentrated using Millipore centrifugation filters, (3
640 kDa molecular weight cutoff). Trypsin digestion was conducted as previously described using a
641 1/40 mass ratio of trypsin/protein [39]. Peptides were recovered and desalted using C18 tips

642 (Rainin). Peptide identification was conducted as previously described using the LTQ-Orbitrap
643 XL mass spectrometer (Thermo) [25]. To identify proteins, searches were carried out against
644 the Uniprot database (downloaded March 21, 2012), with *Cryptococcus* species entered as the
645 taxonomy. This database was concatenated with a fully randomized set of proteins for
646 determination of false-identification rate. Peptides were matched with up to 2 missed trypsin
647 cleavages, carbamidomethylated cysteines as a fixed modification and oxidation of methionine,
648 N-terminal methionine loss with or without acetylation, N-terminal acetylation or oxidation and
649 pyroglutamate from glutamine at the N-terminus as variable modifications. Tolerance for mass
650 accuracy was 20 ppm for parent and 0.8 Da for fragment errors.

651 For protein identification from the database search, the Protein Prospector settings were: 15
652 for the minimum protein score and 10 for the minimum peptide score. The maximum
653 expectation value for proteins was set at 0.009 and for peptides it was 0.05. At the time of this
654 study, the Uniprot database did not contain annotated *C. neoformans* var *grubii* genes, thus
655 protein matches were identified within other *C. neoformans* serotypes and the var *grubii*
656 orthologs were identified by searching the H99 genome either manually or through BLASTp
657 searches using the NCBI nr database (<http://blast.ncbi.nlm.nih.gov/blast/Blast.cgi>).

658 SignalP version 4.0 was used to predict secretion signals, while SecretomeP version 2.0
659 was used to predict non-classical secretion pathways [44,45]. Data are reported in S3 Table.

660 Identification of May1 orthologs was conducted by searching for *CNAG_05872* in FungiDB
661 (www.fungidb.org) [48]. The functional domains of May1 were annotated using BLASTp.
662 Isoelectric point and molecular weights were determined using ExPASy
663 (<http://www.expasy.org/>) [52].

664

665 **Yeast genetics**

666 **Yeast strains:** *C. neoformans* genes were defined by Broad Institute (Cambridge, MA)
667 annotations of the var. *grubii* H99 genome

668 (http://www.broadinstitute.org/annotation/genome/cryptococcus_neoformans/MultiHome.html),
669 where each gene is named numerically as “CNAG_#” [75]. All *C. neoformans* strains used in
670 this study were derived from strain H99 using standard procedures [62] (S4 Table). If
671 unpublished, names for *C. neoformans* peptidases were assigned following the guidelines
672 established in Inglis *et al.* [49].

673 **Preparation of conditioned media:** Yeast cultures were grown in either YNB (1.5 g/L yeast
674 nitrogen base, 5 g/L ammonium sulfate, 2% glucose) or in Dulbecco’s Modified Eagle Medium
675 (DMEM) without phenol red (4.5 g/L glucose, 0.584 g/L L-glutamine, 3.7 g/L NaHCO₃). YNB
676 media is unbuffered and has a starting pH of 5.0, acidifying to a final pH between 1.5-2.0 in
677 saturated cultures, while DMEM is buffered to pH 7.4. For YNB conditioned media, a single
678 yeast colony was inoculated into 100 ml YNB and grown with shaking for a defined duration at
679 30°C (32 hours unless otherwise noted). The cultures were then centrifuged; the supernatant
680 was filtered (0.45 µm), flash frozen and stored at -20°C. For DMEM conditioned media, 90 ODs
681 of log-phase *C. neoformans* cells grown in YNB (the equivalent of 90 ml of a culture at an
682 optical density at 600 nm (OD₆₀₀) of 1) were centrifuged, inoculated into mammalian cell culture
683 dishes containing 25 ml DMEM and maintained in a tissue culture incubator at 37°C with 5%
684 CO₂. After 32 hours (unless otherwise noted), the media was harvested as described above.
685 Because *C. neoformans* responds to light, strains were grown in darkness [76].

686 **Mutant characterization assays:** Overnight YNB cultures were adjusted to an OD₆₀₀ of 5 and
687 3 µL spots of 10-fold dilutions were spotted onto 2% YNB agar plates. Growth at 37°C was
688 measured as well as tolerance to low pH, high pH, NaCl, hydrogen peroxide, sorbitol, caffeine
689 and SDS were measured through inclusion of 25 mM succinic acid, 25 mM MES pH 6.5, 0.75 M
690 NaCl, 0.5 mM peroxide, 1 M sorbitol, 26 mM caffeine and 0.02% SDS respectively.
691 Melanization using L-DOPA containing plates was assayed as previously described [77].
692 Melanization and all plate assays apart from growth at 37°C were conducted at 30°C. Doubling
693 times were calculated using <http://doubling-time.com/compute.php> [78].

694

695 **May1 characterization and enzymatic assays**

696 **Immunoblot:** Samples were collected at the designated time points from liquid YNB cultures
697 and OD₆₀₀ determined. 42 ODs (the equivalent of 42 ml of a culture at an OD₆₀₀ of 1) were then
698 centrifuged and the supernatant removed and frozen. The samples were lyophilized and then
699 dissolved in 0.17 mM Tris base pH 8 and 1X SDS loading dye containing tris(2-
700 carboxyethyl)phosphine. After boiling for 15 minutes the samples were loaded onto a 4-12%
701 Bis-Tris gel and run using MES buffer (Life Technologies). Gels were transferred to
702 nitrocellulose membranes using the iBlot dry transfer system (Life Technologies) and blocked in
703 2% BSA. The monoclonal mouse anti-flag primary antibody (Sigma-Aldrich) diluted 1:2,000 in
704 2% BSA was used followed by HRP conjugated goat anti-mouse secondary antibody (Thermo
705 Scientific) diluted 1:10,000 in 2% BSA. The Luminata Forte Western HRP substrate was used
706 (EMD Millipore) and the blot imaged using a BioRad ChemiDoc imager.

707 **Determination of May1 cleavage site within IQ-2:** Matrix assisted laser desorption ionization-
708 time of flight (MALDI-TOF) analysis was conducted to identify the site of May1 cleavage within
709 IQ-2. 100 µM IQ-2 was digested in a 50 µl assay with 14.6 nM May1 in 100 mM MES, 100 mM
710 NaCl pH 4.5. 10 µl samples were collected at the start of the reaction and after 24 hours.
711 Peptides were recovered and desalted using Rainin C18 tips, lyophilized, and redissolved in
712 5 µl 0.1% formic acid. 0.5 µl of sample was combined with 0.5 µl matrix and analyzed by
713 MALDI-TOF (Shimadzu Biotech Axima Performance).

714 **May1 enrichment:** To concentrate secreted May1, YNB conditioned media was prepared as
715 described above from 32-hour cultures of wild-type *C. neoformans*. The media was then diluted
716 2.7-fold into buffer A (50 mM Tris base pH 8), chosen to increase the pH in order to limit May1
717 autoproteolysis, dilute salts in the media (final conductivity ~6%), and confer a negative charge
718 to the peptidase domain. The media was then loaded onto a 1 ml HiTrap DEAE fast flow
719 column (GE Healthcare) using a fast protein liquid chromatography system with a flow rate of

720 1.5 ml/min. May1 was eluted using a 30 minute linear gradient of 0-100% buffer B (50 mM Tris
721 base, 1 M NaCl, pH 8). Active fractions were determined by measuring activity using the
722 substrate IQ-2. They were then combined and approximate May1 concentration determined by
723 active-site titration.

724 **Active site titration, Km and IC₅₀ calculations:** For the following experiments the plate reader
725 conditions were as described for fluorogenic assays and the substrate used was IQ-2 at 10 μM
726 final concentration since the Km of this substrate was found to be 19.64 μM. Published
727 methods were followed with minor modifications [79]. In brief: May1 active sites were titrated
728 using the potent inhibitor peptstatin A and GraphPad Prism 6 software was used to determine
729 May1 concentration from a plot of V_i/V_o versus the log of inhibitor concentration.

730 Km was determined using 73 nM May1 (100 mM MES 100 mM NaCl pH 4.5) and 0.5 μM to
731 140 μM IQ-2. A correction factor was calculated to adjust for sensitivity of the plate reader by
732 plotting the RFU value of complete cleavage versus the product concentration of IQ-2 from 0.5
733 μM - 10 μM and dividing the V_{max} values from the Km calculation by 1/slope of this line, (units:
734 RFU/[P]). Km was calculated by GraphPad Prism 6 software using the Michaelis-Menten
735 equation.

736 IC₅₀ calculations were conducted using 14.6 nM May1 (100 mM MES 100 mM NaCl pH 4.5).
737 Inhibitor stocks were dissolved in DMSO and incubated with May1 for 10 minutes before
738 addition of substrate. GraphPad Prism 6 was used to calculate IC₅₀ values from a plot of the log
739 of inhibitor concentration versus normalized response.

740 **pH titration of May1 activity:** Concentrated May1 was diluted to 14.6 nM in 100 mM MES,
741 100 mM NaCl buffers from pH 1.5-7. Fluorogenic activity assays were conducted using IQ-2
742 and the conditions described above.

743

744 **Macrophage studies**

745 Bone-marrow derived macrophages (BMDMs) were isolated from C56Bl/6 mice and used for
746 phagocytosis assays as described previously [80]. Briefly, BMDMs were plated in a 96-well
747 plate (10,000/well) and simulated with 100 ng/ml Interferon- γ (Roche) starting 24 hr prior to
748 assay initiation and continuing throughout. Overnight cultures of *C. neoformans* (14-16 hr) were
749 grown in YNB media, after which cells were isolated, washed in DMEM and resuspended in
750 BMDM growth media. Next, cells were opsonized with mAb1255 (10 μ g/ml) at 37°C for 1 hr.
751 *Cryptococcus* cells were added to macrophages at an MOI of 10, and this concentration was
752 confirmed by plating yeast serial dilutions on rich media. After 24 hr at 37°C and 5% CO₂, cells
753 were washed three times with PBS to remove non-adherent yeast. Finally, ~200 BMDMs were
754 quantified per well, with 6 wells per genotype, to determine the fraction of yeast-associated
755 macrophages (phagocytic index).

756 *Cryptococcus* accumulation within macrophages was assessed as described previously
757 [80]. Briefly, BMDMs were plated in 24 well plates at a concentration of 100,000 cells/well.
758 Stimulation was performed as above, after which macrophages were exposed to opsonized *C.*
759 *neoformans* at an MOI of 0.1. After 24 hr at 37°C and 5% CO₂, supernatants were removed and
760 macrophages were lysed. Serial dilutions were plated to determine CFU. The ratio of yeast
761 present at 24 hr versus input was determined and analyzed by bootstrapping, generating 95%
762 confidence intervals.

763

764 **Mouse virulence studies**

765 *C. neoformans* strains were grown in liquid YNB cultures overnight (14-16 hr), and then
766 centrifuged and washed twice in PBS. For competitive co-infection experiments, mixtures of a
767 wild-type strain and a deletion strain of interest were prepared by determining cell concentration
768 using a hemocytometer and then mixing strains in a 1:1 ratio to a final concentration of 1x10⁷
769 cells per ml PBS. Concentrations of viable cells were confirmed by plating serial dilutions. A/J
770 female mice (Jackson Laboratory) aged 5-6 weeks were anesthetized by intraperitoneal

771 injection of ketamine (75 mg/kg) and dexmedetomidine (0.5 mg/kg), then suspended from a silk
772 thread by their front incisors, as described previously [81]. Intranasal infections of 50 μ l were
773 delivered by pipette, resulting in a dose of 5×10^5 cells. After an additional 10 minutes of
774 suspension, the mice were lowered and anesthesia reversed by intraperitoneal injection of
775 atipamezole (1.5 mg/kg). Three mice were infected with each *C. neoformans* genotype, and
776 were monitored until a defined terminal time point of ten days after infection. At this time, mice
777 were sacrificed by CO₂ inhalation and cervical spine dislocation. Next, lungs were harvested
778 and homogenized in PBS using a PRO200 homogenizer (Grainger). The ratios of *C.*
779 *neoformans* strains in the input and organ samples were determined by plating in serial dilutions
780 on Sabouraud agar plates containing 40 mg/ml gentamicin and 50 mg/ml carbenicillin, and then
781 testing the nourseothricin resistance status of ~200 colonies. As a negative control, mice were
782 infected with a 1:1 ratio of wild-type cells and a *sxi1* Δ strain, which is known to have a wild-type
783 phenotype [63].

784 For monotypic infections, female A/J mice were intranasally infected with 50 μ l PBS
785 containing *C. neoformans* cells of a single genotype at a concentration of 1.0×10^7 cells per ml,
786 as described above. Concentrations of viable cells were confirmed by plating serial dilutions.
787 Ten mice were infected per genotype, and were monitored until severe morbidity (as indicated
788 by a loss of 15% of initial body weight or other symptoms), at which point they were sacrificed.
789 Survival data was analyzed using the Online Application for the Survival Analysis of Lifespan
790 Assays Performed in Aging Research [82].

791 **Acknowledgements**

792
793 We thank Dr. Michael Winter (UCSF) for helpful discussions regarding peptidase assays, Dr.
794 Jan Konvalinka (Academy of Sciences of the Czech Republic) for generously sharing aspartyl
795 peptidase inhibitor compounds and Matthew Ravalin (UCSF) for assistance with MALDI-TOF.
796 We would also like to thank Kelly Nissen (UCSF) for thoughtful review of the manuscript and N.
797 Nguyen (UCSF) for media preparation.
798

799
800
801

References

802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847

1. Armstrong-James D, Meintjes G, Brown GD (2014) A neglected epidemic: fungal infections in HIV/AIDS. *Trends Microbiol* 22: 120-127.
2. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. *AIDS* 23: 525-530.
3. Krysan DJ (2015) Toward improved anti-cryptococcal drugs: Novel molecules and repurposed drugs. *Fungal Genet Biol* 78: 93-98.
4. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, et al. (2012) Hidden killers: human fungal infections. *Sci Transl Med* 4: 165rv113.
5. Roemer T, Krysan DJ (2014) Antifungal drug development: challenges, unmet clinical needs, and new approaches. *Cold Spring Harb Perspect Med* 4.
6. Ruiz-Perez F, Nataro JP (2014) Bacterial serine proteases secreted by the autotransporter pathway: classification, specificity, and role in virulence. *Cell Mol Life Sci* 71: 745-770.
7. Kolar SL, Ibarra JA, Rivera FE, Mootz JM, Davenport JE, et al. (2013) Extracellular proteases are key mediators of *Staphylococcus aureus* virulence via the global modulation of virulence-determinant stability. *Microbiologyopen* 2: 18-34.
8. McKerrow JH, Sun E, Rosenthal PJ, Bouvier J (1993) The proteases and pathogenicity of parasitic protozoa. *Annu Rev Microbiol* 47: 821-853.
9. Klemba M, Goldberg DE (2002) Biological roles of proteases in parasitic protozoa. *Annu Rev Biochem* 71: 275-305.
10. Zhang YZ, Ran LY, Li CY, Chen XL (2015) Diversity, Structures, and Collagen-Degrading Mechanisms of Bacterial Collagenolytic Proteases. *Appl Environ Microbiol* 81: 6098-6107.
11. Yang Y, Wen Y, Cai YN, Vallee I, Boireau P, et al. (2015) Serine proteases of parasitic helminths. *Korean J Parasitol* 53: 1-11.
12. Elbaz T, El-Kassas M, Esmat G (2015) New era for management of chronic hepatitis C virus using direct antiviral agents: A review. *J Adv Res* 6: 301-310.
13. Konvalinka J, Krausslich HG, Muller B (2015) Retroviral proteases and their roles in virion maturation. *Virology* 479-480: 403-417.
14. Kaman WE, Hays JP, Endtz HP, Bikker FJ (2014) Bacterial proteases: targets for diagnostics and therapy. *Eur J Clin Microbiol Infect Dis* 33: 1081-1087.
15. Dixit AK, Dixit P, Sharma RL (2008) Immunodiagnostic/protective role of cathepsin L cysteine proteinases secreted by *Fasciola* species. *Vet Parasitol* 154: 177-184.
16. Aoki W, Kitahara N, Fujita A, Shibasaki S, Morisaka H, et al. (2013) Detection of *Candida albicans* by using a designed fluorescence-quenched peptide. *J Biosci Bioeng* 116: 573-575.
17. Yike I (2011) Fungal proteases and their pathophysiological effects. *Mycopathologia* 171: 299-323.
18. Girard V, Dieryckx C, Job C, Job D (2013) Secretomes: the fungal strike force. *Proteomics* 13: 597-608.
19. Alby K, Schaefer D, Bennett RJ (2009) Homothallic and heterothallic mating in the opportunistic pathogen *Candida albicans*. *Nature* 460: 890-893.
20. Naglik J, Albrecht A, Bader O, Hube B (2004) *Candida albicans* proteinases and host/pathogen interactions. *Cell Microbiol* 6: 915-926.

- 848 21. Rambach G, Dum D, Mohsenipour I, Hagleitner M, Wurzner R, et al. (2010) Secretion of a
849 fungal protease represents a complement evasion mechanism in cerebral aspergillosis.
850 Mol Immunol 47: 1438-1449.
- 851 22. Monod M, Capoccia S, Lechenne B, Zaugg C, Holdom M, et al. (2002) Secreted proteases
852 from pathogenic fungi. Int J Med Microbiol 292: 405-419.
- 853 23. Monod M, Borg-von ZM (2002) Secreted aspartic proteases as virulence factors of *Candida*
854 species. Biol Chem 383: 1087-1093.
- 855 24. Baldo A, Monod M, Mathy A, Cambier L, Bagut ET, et al. (2012) Mechanisms of skin
856 adherence and invasion by dermatophytes. Mycoses 55: 218-223.
- 857 25. O'Donoghue AJ, Knudsen GM, Beekman C, Perry JA, Johnson AD, et al. (2015) Destructin-
858 1 is a collagen-degrading endopeptidase secreted by *Pseudogymnoascus destructans*,
859 the causative agent of white-nose syndrome. Proc Natl Acad Sci U S A 112: 7478-7483.
- 860 26. Sriranganadane D, Waridel P, Salamin K, Feuermann M, Mignon B, et al. (2011)
861 Identification of novel secreted proteases during extracellular proteolysis by
862 dermatophytes at acidic pH. Proteomics 11: 4422-4433.
- 863 27. Eigenheer RA, Jin Lee Y, Blumwald E, Phinney BS, Gelli A (2007) Extracellular
864 glycosylphosphatidylinositol-anchored mannoproteins and proteases of *Cryptococcus*
865 *neoformans*. FEMS Yeast Res 7: 499-510.
- 866 28. Vu K, Tham R, Uhrig JP, Thompson GR, 3rd, Na Pombejra S, et al. (2014) Invasion of the
867 central nervous system by *Cryptococcus neoformans* requires a secreted fungal
868 metalloprotease. MBio 5: e01101-01114.
- 869 29. Campbell LT, Simonin AR, Chen C, Ferdous J, Padula MP, et al. (2015) *Cryptococcus*
870 strains with different pathogenic potentials have diverse protein secretomes. Eukaryot
871 Cell 14: 554-563.
- 872 30. Casadevall A, Steenbergen JN, Nosanchuk JD (2003) 'Ready made' virulence and 'dual
873 use' virulence factors in pathogenic environmental fungi--the *Cryptococcus neoformans*
874 paradigm. Curr Opin Microbiol 6: 332-337.
- 875 31. Yoo Ji J, Lee YS, Song CY, Kim BS (2004) Purification and characterization of a 43-
876 kilodalton extracellular serine proteinase from *Cryptococcus neoformans*. J Clin
877 Microbiol 42: 722-726.
- 878 32. Pinti M, Orsi CF, Gibellini L, Esposito R, Cossarizza A, et al. (2007) Identification and
879 characterization of an aspartyl protease from *Cryptococcus neoformans*. FEBS Lett 581:
880 3882-3886.
- 881 33. Aoki S, Ito-Kuwa S, Nakamura K, Kato J, Ninomiya K, et al. (1994) Extracellular proteolytic
882 activity of *Cryptococcus neoformans*. Mycopathologia 128: 143-150.
- 883 34. Rodrigues ML, dos Reis FC, Puccia R, Travassos LR, Alviano CS (2003) Cleavage of
884 human fibronectin and other basement membrane-associated proteins by a
885 *Cryptococcus neoformans* serine proteinase. Microb Pathog 34: 65-71.
- 886 35. Ruma-Haynes P, Brownlee AG, Sorrell TC (2000) A rapid method for detecting extracellular
887 proteinase activity in *Cryptococcus neoformans* and a survey of 63 isolates. J Med
888 Microbiol 49: 733-737.
- 889 36. Chan MY, Tay ST (2010) Enzymatic characterisation of clinical isolates of *Cryptococcus*
890 *neoformans*, *Cryptococcus gattii* and other environmental *Cryptococcus* spp. Mycoses
891 53: 26-31.
- 892 37. Vidotto V, Koga-Ito CY, Canella D, Sinicco A, Di Perri G, et al. (2000) Extracellular activity in
893 *Cryptococcus neoformans* strains isolated from AIDS patients and from environmental
894 sources. Rev Iberoam Micol 17: 14-19.
- 895 38. Vidotto V, Melhem M, Pukinskas S, Aoki S, Carrara C, et al. (2005) Extracellular enzymatic
896 activity and serotype of *Cryptococcus neoformans* strains isolated from AIDS patients in
897 Brazil. Rev Iberoam Micol 22: 29-33.

- 898 39. O'Donoghue AJ, Eroy-Reveles AA, Knudsen GM, Ingram J, Zhou M, et al. (2012) Global
899 identification of peptidase specificity by multiplex substrate profiling. *Nat Methods* 9:
900 1095-1100.
- 901 40. O'Brien TC, Mackey ZB, Fetter RD, Choe Y, O'Donoghue AJ, et al. (2008) A parasite
902 cysteine protease is key to host protein degradation and iron acquisition. *J Biol Chem*
903 283: 28934-28943.
- 904 41. Small JL, O'Donoghue AJ, Boritsch EC, Tsodikov OV, Knudsen GM, et al. (2013) Substrate
905 specificity of MarP, a periplasmic protease required for resistance to acid and oxidative
906 stress in *Mycobacterium tuberculosis*. *J Biol Chem* 288: 12489-12499.
- 907 42. O'Donoghue AJ, Mahon CS, Goetz DH, O'Malley JM, Gallagher DM, et al. (2008) Inhibition
908 of a secreted glutamic peptidase prevents growth of the fungus *Talaromyces emersonii*.
909 *J Biol Chem* 283: 29186-29195.
- 910 43. Geddes JM, Croll D, Caza M, Stoyanov N, Foster LJ, et al. (2015) Secretome profiling of
911 *Cryptococcus neoformans* reveals regulation of a subset of virulence-associated
912 proteins and potential biomarkers by protein kinase A. *BMC Microbiol* 15: 206.
- 913 44. Petersen TN, Brunak S, von Heijne G, Nielsen H (2011) SignalP 4.0: discriminating signal
914 peptides from transmembrane regions. *Nat Methods* 8: 785-786.
- 915 45. Bendtsen JD, Jensen LJ, Blom N, Von Heijne G, Brunak S (2004) Feature-based prediction
916 of non-classical and leaderless protein secretion. *Protein Eng Des Sel* 17: 349-356.
- 917 46. Rodrigues ML, Nakayasu ES, Oliveira DL, Nimrichter L, Nosanchuk JD, et al. (2008)
918 Extracellular vesicles produced by *Cryptococcus neoformans* contain protein
919 components associated with virulence. *Eukaryot Cell* 7: 58-67.
- 920 47. Levitz SM, Specht CA (2006) The molecular basis for the immunogenicity of *Cryptococcus*
921 *neoformans* mannoproteins. *FEMS Yeast Res* 6: 513-524.
- 922 48. Stajich JE, Harris T, Brunk BP, Brestelli J, Fischer S, et al. (2012) FungiDB: an integrated
923 functional genomics database for fungi. *Nucleic Acids Res* 40: D675-681.
- 924 49. Inglis DO, Skrzypek MS, Liaw E, Muktali V, Sherlock G, et al. (2014) Literature-based gene
925 curation and proposed genetic nomenclature for *cryptococcus*. *Eukaryot Cell* 13: 878-
926 883.
- 927 50. Colaert N, Helsens K, Martens L, Vandekerckhove J, Gevaert K (2009) Improved
928 visualization of protein consensus sequences by iceLogo. *Nat Methods* 6: 786-787.
- 929 51. Rawlings ND, Waller M, Barrett AJ, Bateman A (2014) MEROPS: the database of proteolytic
930 enzymes, their substrates and inhibitors. *Nucleic Acids Res* 42: D503-509.
- 931 52. Artimo P, Jonnalagedda M, Arnold K, Baratin D, Csardi G, et al. (2012) ExPASy: SIB
932 bioinformatics resource portal. *Nucleic Acids Res* 40: W597-603.
- 933 53. Letunic I, Doerks T, Bork P (2015) SMART: recent updates, new developments and status
934 in 2015. *Nucleic Acids Res* 43: D257-260.
- 935 54. Sansen S, De Ranter CJ, Gebruers K, Brijs K, Courtin CM, et al. (2004) Structural basis for
936 inhibition of *Aspergillus niger* xylanase by *triticum aestivum* xylanase inhibitor-I. *J Biol*
937 *Chem* 279: 36022-36028.
- 938 55. Dunn BM (2001) Overview of pepsin-like aspartic peptidases. *Curr Protoc Protein Sci*
939 Chapter 21: Unit 21 23.
- 940 56. Rinnova M, Hradilek M, Barinka C, Weber J, Soucek M, et al. (2000) A picomolar inhibitor of
941 resistant strains of human immunodeficiency virus protease identified by a combinatorial
942 approach. *Arch Biochem Biophys* 382: 22-30.
- 943 57. Skalova T, Hasek J, Dohnalek J, Petrokova H, Buchtelova E, et al. (2003) An ethylenamine
944 inhibitor binds tightly to both wild type and mutant HIV-1 proteases. Structure and energy
945 study. *J Med Chem* 46: 1636-1644.
- 946 58. Skalova T, Dohnalek J, Duskova J, Petrokova H, Hradilek M, et al. (2006) HIV-1 protease
947 mutations and inhibitor modifications monitored on a series of complexes. Structural
948 basis for the effect of the A71V mutation on the active site. *J Med Chem* 49: 5777-5784.

- 949 59. Petrokova H, Duskova J, Dohnalek J, Skalova T, Vondrackova-Buchtelova E, et al. (2004)
950 Role of hydroxyl group and R/S configuration of isostere in binding properties of HIV-1
951 protease inhibitors. *Eur J Biochem* 271: 4451-4461.
- 952 60. Sidrim JJ, Perdigao-Neto LV, Cordeiro RA, Brilhante RS, Leite JJ, et al. (2012) Viral
953 protease inhibitors affect the production of virulence factors in *Cryptococcus*
954 *neoformans*. *Can J Microbiol* 58: 932-936.
- 955 61. Monari C, Pericolini E, Bistoni G, Cenci E, Bistoni F, et al. (2005) Influence of indinavir on
956 virulence and growth of *Cryptococcus neoformans*. *J Infect Dis* 191: 307-311.
- 957 62. Chun CD, Madhani HD (2010) Applying genetics and molecular biology to the study of the
958 human pathogen *Cryptococcus neoformans*. *Methods Enzymol* 470: 797-831.
- 959 63. Hull CM, Cox GM, Heitman J (2004) The alpha-specific cell identity factor Sxi1alpha is not
960 required for virulence of *Cryptococcus neoformans*. *Infect Immun* 72: 3643-3645.
- 961 64. Naglik JR, Challacombe SJ, Hube B (2003) *Candida albicans* secreted aspartyl proteinases
962 in virulence and pathogenesis. *Microbiol Mol Biol Rev* 67: 400-428, table of contents.
- 963 65. Nessa K, Gross NT, Jarstrand C, Johansson A, Camner P (1997) In vivo interaction
964 between alveolar macrophages and *Cryptococcus neoformans*. *Mycopathologia* 139: 1-
965 7.
- 966 66. Levitz SM, Nong SH, Seetoo KF, Harrison TS, Speizer RA, et al. (1999) *Cryptococcus*
967 *neoformans* resides in an acidic phagolysosome of human macrophages. *Infect Immun*
968 67: 885-890.
- 969 67. Byrnes EJ, 3rd, Li W, Lewit Y, Ma H, Voelz K, et al. (2010) Emergence and pathogenicity of
970 highly virulent *Cryptococcus gattii* genotypes in the northwest United States. *PLoS*
971 *Pathog* 6: e1000850.
- 972 68. Vickers I, Reeves EP, Kavanagh KA, Doyle S (2007) Isolation, activity and immunological
973 characterisation of a secreted aspartic protease, CtsD, from *Aspergillus fumigatus*.
974 *Protein Expr Purif* 53: 216-224.
- 975 69. Stewart K, Abad-Zapatero C (2001) *Candida* proteases and their inhibition: prospects for
976 antifungal therapy. *Curr Med Chem* 8: 941-948.
- 977 70. Pozio E, Morales MA (2005) The impact of HIV-protease inhibitors on opportunistic
978 parasites. *Trends Parasitol* 21: 58-63.
- 979 71. Dos Santos AL (2011) Protease expression by microorganisms and its relevance to crucial
980 physiological/pathological events. *World J Biol Chem* 2: 48-58.
- 981 72. Mehra T, Koberle M, Braunsdorf C, Mailander-Sanchez D, Borelli C, et al. (2012) Alternative
982 approaches to antifungal therapies. *Exp Dermatol* 21: 778-782.
- 983 73. Olsen I, Potempa J (2014) Strategies for the inhibition of gingipains for the potential
984 treatment of periodontitis and associated systemic diseases. *J Oral Microbiol* 6.
- 985 74. Chalkley RJ, Baker PR, Medzihradzsky KF, Lynn AJ, Burlingame AL (2008) In-depth
986 analysis of tandem mass spectrometry data from disparate instrument types. *Mol Cell*
987 *Proteomics* 7: 2386-2398.
- 988 75. Institute B (2008) *Cryptococcus* Sequencing initiative, Broad Institute (broadinstitute.org).
- 989 76. Idnurm A, Heitman J (2005) Photosensing fungi: phytochrome in the spotlight. *Curr Biol* 15:
990 R829-832.
- 991 77. Liu OW, Chun CD, Chow ED, Chen C, Madhani HD, et al. (2008) Systematic genetic
992 analysis of virulence in the human fungal pathogen *Cryptococcus neoformans*. *Cell* 135:
993 174-188.
- 994 78. Roth V (2006) Doubling Time. Available: <http://doubling-time.com/compute.php>.
- 995 79. Furfine ES (2001) HIV protease assays. *Curr Protoc Pharmacol* Chapter 3: Unit3 2.
- 996 80. Homer CM, Summers DK, Goranov AI, Clarke SC, Wiesner DL, et al. (2016) Intracellular
997 Action of a Secreted Peptide Required for Fungal Virulence. *Cell Host Microbe* 19: 849-
998 864.

- 999 81. Cox GM, Mukherjee J, Cole GT, Casadevall A, Perfect JR (2000) Urease as a virulence
1000 factor in experimental cryptococcosis. *Infect Immun* 68: 443-448.
1001 82. Yang JS, Nam HJ, Seo M, Han SK, Choi Y, et al. (2011) OASIS: online application for the
1002 survival analysis of lifespan assays performed in aging research. *PLoS One* 6: e23525.

1003

1004 **Supporting information captions**

1005

1006 **S1 Fig. Fluorogenic assays indicate the endopeptidase class present in conditioned**
1007 **media and the optimal pH for detection of activity.** (A) The impact of class specific
1008 peptidase inhibitors on peptidase activity. The class of enzyme inhibited by each compound is
1009 indicated in parenthesis. Averages and S.D. are shown for triplicates. The substrates cleaved
1010 most efficiently by peptidases in each media condition are shown (IQ-2 and IQ-7 for YNB and
1011 DMEM, respectively). Cleavage of the other IQ substrates by conditioned YNB media was also
1012 sensitive to pepstatin A, while cleavage of the other IQ substrates by DMEM conditioned media
1013 were also sensitive to 1-10-phenanthroline. (B) Screen of the effect of pH on proteolytic activity
1014 in YNB and DMEM supernatants. Three efficiently cleaved IQ substrates were chosen for this
1015 analysis. The activity scale is differs for this experiment because this assay was conducted on
1016 a SpectraMax Gemini plate reader (Molecular Devices) although conditions were otherwise
1017 equivalent. Averages and S.D. are shown for triplicates.

1018 **S2 Fig. Reproducibility of MSP-MS assay.** (A) YNB media conditioned by wild type *C.*
1019 *neoformans* was incubated with the 228-member MSP-MS peptide library for 15, 60, 240, and
1020 1200 minutes. The number of cleavage sites was assessed at each time point, in triplicate.
1021 Error bars represent S.D. (B) Overlap of MSP-MS cleavage sites at the 1200 minute time point,
1022 among three replicates. (C-E) Substrate specificity profile of YNB media conditioned by wild
1023 type *C. neoformans*, as assessed in three technical replicates.

1024

1025 **S3 Fig. Functional categorization and analysis of secretion mechanism for proteomics**
1026 **results.** (A) Functional categorization of all 24 proteins predicted to have a secretion signal.
1027 Functions were determined for unannotated proteins by the closest annotated protein after
1028 conducting a Blastp search. (B) Analysis of predicted secretion method for all proteins detected
1029 in YNB or DMEM conditioned media by proteomics.

1030

1031 **S4 Fig. MSP-MS analysis of secreted peptidase activity in *prb1Δ*, *CNAG_00150Δ*, *scx1Δ***
1032 **and *cxd1Δ* strains cultured in DMEM.** (A) Substrate specificity profiles of the serine peptidase
1033 deletion strains *prb1Δ* and *CNAG_00150Δ* and the carboxypeptidase deletion strains *scx1Δ* and
1034 *cxd1Δ* grown in DMEM, $p < 0.05$. (B) Positional analysis of the bonds cleaved in the four
1035 deletion strains. (C) Representative example of a peptide cleaved by peptidases in media
1036 conditioned by each of the four deletion strains.

1037

1038 **S5 Fig. MSP-MS analysis of secreted peptidase activity in *cxd2Δ*, *cxd3Δ* and *pep4Δ***

1039 **strains cultured in YNB media.** (A) Substrate specificity profiles of the carboxypeptidase
1040 deletion strains *cx_d2 Δ* and *cx_d3 Δ* as well as the aspartyl peptidase deletion strain *pep4 Δ* grown
1041 in YNB, $p < 0.05$. (B) Positional analysis of the bonds cleaved in the four deletion strains. (C)
1042 An example of a representative peptide cleaved by conditioned media from each deletion strain.

1043
1044 **S6 Fig. IQ-2 is cleaved by May1.** (A) Proteolysis of IQ-2 was measured in a fluorogenic assay
1045 of YNB supernatants from all peptidase deletion strains. Deletion of *MAY1* led to complete loss
1046 of cleavage of IQ-2. Columns represent mean \pm S.D. (B) May1 was diluted to 14.6 nM in 100
1047 mM MES pH 4.5, 100 mM NaCl and incubated with IQ-2. At the start of the reaction and after
1048 24 hours of incubation at room temperature, samples were collected and analyzed by Matrix
1049 Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF). Based on analysis of its
1050 substrate specificity, it was hypothesized that May1 would cleave between the phenylalanine
1051 and leucine in IQ-2. The sodium adduct was observed for the N-terminal fragment of the
1052 expected cleavage product, confirming the site of cleavage.

1053
1054 **S7 Fig. Growth curves for all peptidase deletion strains.** OD₆₀₀ measurements were
1055 recorded for cultures grown in triplicate. Averages and S.D. of triplicates are shown.

1056
1057 **S8 Fig. Temperature and pH tolerance of peptidase deletion strains.** (A) Two independent
1058 isolates of each peptidase deletion strain were spotted in a 10-fold dilution series on YNB agar
1059 plates and grown for 48 hours before imaging. (B) pH tolerance of *may1 Δ* strains after 72 hours
1060 of growth.

1061
1062 **S9 Fig. Tolerance to solute, peroxide and cell wall stress and production of melanin of
1063 peptidase deletion strains.** (A) 10-fold dilution series of all peptidase deletion strains were
1064 spotted on YNB agar plates containing the indicated stress and grown for 48 hours, except for
1065 H₂O₂ plates, which were grown for four days before imaging. (B) 10-fold dilution series of
1066 peptidase deletion strains grown on rich media plates (YPAD) containing 0.02% SDS and
1067 imaged after four days of growth. (C) Melanin production in the presence of L-DOPA. Strains
1068 were spotted in triplicate and images were taken after 72 hours of growth.

1069
1070 **S10 Fig. Screen of aspartyl peptidase inhibitors.** Panels (A), (B) and (C) show the results of
1071 each inhibitor compound tested in triplicate at 100 μ M, 10 μ M and 1 μ M. The May1 activity
1072 against IQ-2 was measured. The average value and S.D. of triplicates are shown. (D) IC₅₀
1073 values were calculated for Brecanavir, pepstatin A and compounds 4, 16, 18 and 21. Values
1074 are averaged from triplicates and S.D. is shown by error bars.

1075
1076 **S11 Fig. May1 activity in cultures treated with aspartyl peptidase inhibitors.** (A) Activity
1077 was recorded against the substrate IQ-2. Average values and S.D. of triplicate measurements
1078 are shown. (B) Density at saturation (after 48 hours of growth) is shown for YNB cultures of wild
1079 type or *may1 Δ* *C. neoformans* treated with May1 inhibitors. Average values and S.D. of
1080 triplicates are shown.

1081
1082 **S12 Fig. May1 is required for *C. neoformans* accumulation in macrophages.** (A)
1083 Phagocytic index of opsonized *C. neoformans*. Error bars represent S.D. (B) Intracellular
1084 accumulation of *C. neoformans* in macrophages. * $p < 0.05$ versus wild type control. Error bars
1085 represent 95% confidence intervals.

1086
1087 **S1 Table.** Sequences of internally quenched fluorogenic substrates. All peptides contain

1088 an N-terminal fluorophore: aminomethylcoumarin bound to the side chain of lysine or directly to
1089 the N-terminus as indicated, and a C-terminal quencher: di-nitrophenol bound to the side chain
1090 of lysine or directly to the C-terminus as indicated. “t” represents tert-butyl glycine and “n”
1091 represents norleucine.

1092
1093 **S2 Table. Pearson correlations among of MSP-MS assay results and technical replicates.**
1094 YNB media conditioned by wild type *C. neoformans* was incubated with the 228-member MSP-
1095 MS peptide library in three technical replicates. In each replicate, the frequency of every amino
1096 acid found at each of the 8 positions surrounding the cleaved bond was assessed. P4-P4'
1097 substrate specificity profiles were then created and compared using Pearson correlation.
1098 Correlation between the substrate specificity profiles of YNB media conditioned by wild type
1099 versus mutant strains was assessed in a similar manner.

1100
1101 **S3 Table. Proteins identified by proteomics analysis.** 32-hour YNB supernatants and 48-
1102 hour DMEM supernatants from wild-type *C. neoformans* cultures were analyzed. Since *C.*
1103 *neoformans* var *grubii* genes were not annotated in the version of the Uniprot database
1104 available, peptides were matched to proteins in other serotypes and the Uniprot accession
1105 numbers for *C. neoformans* var *grubii* proteins were then manually identified. “E value” stands
1106 for expectation value. An asterisk in the corresponding column indicates if a protein has a
1107 predicted secretion signal [44], is expected to be non-classically secreted [45] or has been
1108 associated with secreted microvesicles [46]. As indicated, after repeating proteomic analysis of
1109 the 32-hour YNB sample one additional peptidase was identified.

1110
1111 **S4 Table. Expanded strain information.** All strains used in this study are indicated, along with
1112 the CM number denoting their location in the Madhani laboratory strain database. “Nat^R”
1113 indicates nourseothricin resistance, under the column labeled source “1” indicates a gift of J.
1114 Lodge, while “2” indicates strains created for this study.

1115
1116 **S5 Table. Peptides observed by MSP-MS.** All peptides detected by MSP-MS for each strain
1117 profiled are listed, as well as the reference set used to construct iceLogos from each dataset.
1118 An “n” is used to indicate norleucine, a replacement for methionine in the peptide library.

1119
1120 **S6 Table. Doubling times and saturation densities of strains grown in YNB.** Values shown
1121 are averages of triplicates grown in 25 mL YNB cultures. The online doubling time calculator
1122 was used to estimate doubling times during the exponential growth phase [78].

1123
1124 **S7 Table. Aspartyl peptidase inhibitors.** Structures of the 21 peptidomimetic aspartyl
1125 peptidase inhibitors used in this study as well as their effectiveness at inhibiting May1 activity at
1126 1 μM concentration. Ten HIV protease inhibitors were also assessed.